Compare Campbell Soup Co. (CPB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs State Street SPDR S&P Biotech ETF — how do they compare? Campbell Soup Co. trades at $19.21 (market cap $5.78B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and Campbell Soup Co. pays a 5.16% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Campbell Soup Co. for 98 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| CPB | XBI | |
|---|---|---|
Market Cap | $5.78B | $10.11B |
Volume | 11,705,427 | 12,903,266 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $31.66 | $169.55 |
52-Week Low | $18.90 | $104.99 |
Typical Hold Time | 98 Days | 38 Days |
Enterprise Value | $12.83B | — |
Dividend Yield | 5.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's (CPB) trades at $19.37, up 2.49% today, but faces significant headwinds with a recent 36% dividend cut and bearish technical signals. The stock shows mixed earnings performance with two recent beats but a Q4 2026 miss, while fundamentals reveal modest revenue growth to $10.25B but declining net margins to 4.14%. Analyst sentiment remains cautious with only 3.45% buy ratings amid ongoing restructuring efforts.
The outlook remains challenging with weak FY2027 guidance and margin pressure, though current valuation (P/E 14.79) may attract value investors. Key risks include execution of $500M cost savings plan, competitive pressures, and consumer spending trends. The dividend yield near 5% post-cut offers income potential but requires careful monitoring of cash flow sustainability.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
